7月30日,礼来公司宣布,其非共价BTK抑制剂吡妥布替尼(Jaypirca)在关键性三期临床试验BRUIN CLL-314中取得突破性成果。该研究直接对比吡妥布替尼与目前广泛使用的共价BTK抑制剂伊布替尼(Imbruvica)在慢性淋巴细胞白血病(CLL)或小淋巴细胞淋巴瘤(SLL)患者中的疗效。这是首个纳入初治患者、针对共价BTK抑制剂的头对头III期研究。研究结果显示,吡妥布替尼达到了主要终点...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.